Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Sara A. Hurvitz(University of Washington), Javier Cortés(Villa Maria Hospital), Giuseppe Curigliano(European Institute of Oncology), Winnie Yeo(Chinese University of Hong Kong), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Hiroji Iwata(Aichi Cancer Center), Sherene Loi(The University of Melbourne), Junji Tsurutani(SHOWA Medical University), Shahid Ashfaque(Daiichi Sankyo (United States)), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Roberto Hegg, Vinod Ganju(Peninsula Health), Sung‐Bae Kim(Ulsan College), Chiun‐Sheng Huang(National Taiwan University Hospital), Jan‐Willem Henning, Jean‐Sébastien Frenel(Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers), Silvia Antolín(Universidade da Coruña), Vanessa Petry(Instituto do Câncer do Estado de São Paulo), Giampaolo Bianchini(Vita-Salute San Raffaele University), William Jacot(Inserm), Wei‐Pang Chung(National Cheng Kung University Hospital), Seock‐Ah Im(Seoul National University), Jillian Cathcart(Daiichi Sankyo (Germany)), José Manuel Pérez-García(MedSIR (Spain)), Wěi Li(Shougang (China)), Yali Liu(Daiichi Sankyo (United States)), Sevilay Altıntaş(Antwerp University Hospital), Anton Egorov(Daiichi Sankyo (United States)), Joanne Wing Yan Chiu(Children's Hospital of Los Angeles), Erika Hamilton(Sarah Cannon)

The Lancet

December 7, 2022

Cited by 664

|New England Journal of Medicine|2010|4.5k

|New England Journal of Medicine|2020|3.1k

|New England Journal of Medicine|2016|2.9k

|Nature Reviews Disease Primers|2019|2.9k

|New England Journal of Medicine|2022|2.5k

Related Papers